









Markets
/
Stocks
/
nasdaq-bngo
/

Bionano Genomics Inc

BNGO

1.150USD

+0.025+2.22%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

11.19MMarket Cap

LossP/E TTM



Bionano Genomics Inc

1.150

+0.025+2.22%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bionano Genomics Inc

Currency: USD Updated: 2026-02-06

Key Insights

Bionano Genomics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 132 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.50.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bionano Genomics Inc's Score

Industry at a Glance

Industry Ranking

132 / 205

Overall Ranking

380 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Bionano Genomics Inc Highlights

StrengthsRisks

Bionano Genomics, Inc. is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company offers optical genome mapping (OGM) solutions for applications across basic, translational and clinical research. It also offers a platform-agnostic software solution, which integrates sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants, and absence of heterozygosity across the genome in one consolidated view. The Company additionally offers nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. The Company markets and sells OGM systems, including the Saphyr system, which delivers OGM data to enable ultra-sensitive and ultra-specific detection of all classes of structural variation (SV).

Growing

The company is in a growing phase, with the latest annual income totaling USD 30.78M.

Overvalued

The company’s latest PE is -0.00, at a high 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 82.31K shares of this stock.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.500

Target Price

+532.91%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Bionano Genomics Inc is 6.01, ranking 175 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 7.37M, representing a year-over-year increase of 21.31%, while its net profit experienced a year-over-year increase of 80.78%.

Score

Industry at a Glance

Previous score

6.01

Change



Financials

5.54

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.15

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

4.22

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.06

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Bionano Genomics Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Bionano Genomics Inc is 8.18, ranking 44 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.00, which is 0.00% below the recent high of -0.00 and -2148300.00% above the recent low of -4.30.

Score

Industry at a Glance

Previous score

8.18

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 132/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Bionano Genomics Inc is 7.33, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 7.50, with a high of 8.00 and a low of 7.00.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

7.500

Target Price

+532.91%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Bionano Genomics Inc

BNGO

Intuitive Surgical Inc

ISRG

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Bionano Genomics Inc is 1.40, ranking 203 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 1.58 and the support level at 0.89, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

1.39

Change

0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.082

Sell

RSI(14)

26.956

Sell

STOCH(KDJ)(9,3,3)

14.257

Oversold

ATR(14)

0.121

High Vlolatility

CCI(14)

-108.266

Sell

Williams %R

86.957

Oversold

TRIX(12,20)

-0.838

Sell

StochRSI(14)

48.887

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.186

Sell

MA10

1.328

Sell

MA20

1.446

Sell

MA50

1.551

Sell

MA100

1.668

Sell

MA200

2.630

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Bionano Genomics Inc is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 2.31%, representing a quarter-over-quarter decrease of 10.20%. The largest institutional shareholder is The Vanguard, holding a total of 82.31K shares, representing 0.81% of shares outstanding, with 51.34% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Lincoln Alternative Strategies LLC

525.00K

Heights Capital Management, Inc.

475.00K

Abbe (Richard)

322.53K

Iroquois Capital Management, LLC

194.66K

The Vanguard Group, Inc.

Star Investors

50.46K

Geode Capital Management, L.L.C.

26.84K

+42.22%

Carret Asset Management, LLC

25.00K

HRT Financial LP

20.33K

Two Sigma Investments, LP

15.58K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bionano Genomics Inc is 3.33, ranking 129 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.69. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.